157 Clinicopathological implications of cyclin B1, cdc2, p16 and p53 expression in breast cancer

Abstract

surgery from 1986 to 1995. Premenopausal women were treated with adjuvant ovarian ablation by irradiation and postmenopausal women with adjuvant Tamoxifen for 5 years. Steroid receptors contents were determined prospectively by the classical biochemical DCC method, while HER2 gene amplification was determined retrospectively by CISH in 134 women whose archival paraffin tissue samples were retrieved. Results: One hundred and thirty four patients whose HER2 status was determined (66 premenopausal and 68 postmenopausal) of median age of 51 years (range 35−76), were followed for median 11.8 years (range 0.9−19). Eleven (8.21%) patients were node negative with grade 3 BC and 125 (93.28%) had 1−3 positive nodes irrespective of tumor grade. Median disease free interval was 12.3 years (95%CI 10–17.8); median BC specific survival (BCSS) was 16.2 years (95%CI 13-Inf) and overall survival (OS) was 15.2 years (95%CI 12.1-Inf). HER2 gene amplification (CISH+) were noted in 21 (15.67%), while 113 (84.33%) had no HER2 gene amplification (CISH−). There was no significant difference in the risk for disease relapse [HR 1.25 (95%CI 0.678–2.29), p = 0.489], death from BC [HR 1.21 (95%CI (0.608–2.42), p = 0.591], and death from any cause [1.19 (0.637–2.23), p = 0.590] between CISH+ and CISH− subgroup. Cox regression analysis showed that only ER-/PgR+ status was an independent favorable risk factor for BCSS [HR 8.29 (95%CI 1.14–60.24, Wald test p = 0.028)] and OS [HR 7.51 (95%CI 1.31–68.97, Wald test p = 0.0009)]. Comparison between premenopausal and postmenopausal subgroups with CISH+ BC showed a trend toward longer OS in premenopausal women (Log rank test c1= 3.302, p = 0.069), while the OS difference in CISH− group reached statistical significance in premenopausal women (Log rank test c1= 4.849, p = 0.028). However, there was no difference in BCSS between premenopausal and postmenopausal subgroups regardless of HER2 status. Conclusion: Our results did not show that positive HER2 status had a significant influence on disease outcome in early SR-positive breast cancer patients treated with adjuvant endocrine therapy only.